|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Department of Haematology, Addenbrooke's NHS
Trust, Cambridge, United Kingdom
Cytochrome P-450 2C9 is the principle enzyme that terminates the
anticoagulant effect of warfarin. Genetic polymorphisms in CYP2C9 producing variants with altered catalytic properties
have been identified. Patients (n = 561) with a target international normalized ratio (INR) of 2.5 who had been treated with warfarin for
more than 2 months were anonymously genotyped for the wild-type CYP2C9*1 allele and the 2C9*2 and
2C9*3 variants. The mean maintenance dose of warfarin in
patients who were wild-type for both alleles was 5.01 mg. The
maintenance dose of warfarin was significantly related to genotype
(Kruskall-Wallis, The clinical effectiveness of warfarin is
established. However, because of a low therapeutic index, bleeding
frequently complicates anticoagulation with warfarin. Overall, the
bleeding rate is 7.6 to 16.5 per hundred patient-years. Major or
life-threatening bleeds occur at a rate of 1.3 to 2.7 per hundred
patient-years.1-3 Although major bleeding can occur at
therapeutic levels the risk of bleeding rises with increasing intensity
of anticoagulation.1-4 The international normalized ratio
(INR) is commonly adopted for laboratory monitoring of oral
anticoagulant therapy and as a guide to warfarin dose adjustment.5 Because the risk of bleeding increases with
increasing intensity of anticoagulation, identification of risk factors
for the development of a high INR may identify patients at high risk of
bleeding. Cytochrome P-450 2C9 is the principle enzyme that terminates
the anticoagulant effect of warfarin by catalyzing the conversion of
the pharmacologically more potent S-enantiomer to its inactive
metabolites. Genetic polymorphisms in CYP2C9 producing variants with altered catalytic properties have been
identified.6 In addition to the wild-type
CYP2C9*1 allele, 2 allelic variants, 2C9*2
(R144C) and 2C9*3 (I359L), with approximately 12% and 5% enzymatic activity, respectively, have been identified.7-9
Patients with variant alleles might be susceptible to
over-anticoagulation during intercurrent illness or during a change of
medication, particularly if an additional drug is competitively
metabolized by the cytochrome P-450 system. In a previous study the
2C9*2 and 2C9*3 alleles were more frequent in
patients with a daily warfarin dose requirement of 1.5 mg or less
immediately after initiation of therapy.10 Patients with a
low-dose requirement were more likely to have an INR more than 4.0 during induction of therapy (OR 5.97, 95% CI 2.26-15.82) and have an
increased risk of major bleeding complications during induction (OR
3.68, 95% CI 1.43-9.50). The aim of this study was to determine the pharmacogenetic effect of CYP2C9 polymorphisms on warfarin
sensitivity and the risk of over-anticoagulation in patients receiving
long-term warfarin treatment.
Patient population and study methodology
Measurement of INR
Genotyping Genotyping was performed by multiplex polymerase chain reaction (PCR) and restriction enzyme digestion with AvaII and NsiI. The 2C9*2 allele is the result of a C416T transition in exon 3. This results in the loss of an AvaII restriction digest site. PCR was performed with primers, 5'-CAA TGG AAA GAA ATG GAA GGA GGT-3' (location 331-354) and 5'-AGA AAG TAA TAC TCA GAC CAA CAA TCG-3' (location 555-581). A forced mismatch was included in the penultimate base of the forward primer to create a control site for AvaII digestion. The PCR product from this amplification is 251 bp in length. After AvaII digestion, patients homozygous for the wild-type allele have 170- and 60-bp fragments, patients homozygous for the 2C9*2 allele have 229-bp fragments, and those heterozygous for 2C9*2 have 229-, 170-, and 60-bp fragments. The 2C9*3 allele does not naturally create or destroy a restriction site. A restriction site was forced into the forward primer 5'-TGC ACG AGG TCC AGA GAT GC-3' (location 1041-1060), such that A1061 in combination with the mismatch creates a restriction site for the NsiI restriction enzyme. The 2C9*3 A1061C substitution removes this restriction site. This primer also naturally includes an AvaII restriction sequence (GGTCC). The reverse primer, 5'-AGC TTC AGG GTT TAC GTA TCA TAG TAA-3' (location 1172-1198) also has a forced mismatch at 1186 to provide a control restriction site for the NsiI restriction enzyme. The PCR product for this set of primers prior to restriction enzyme digestion is 160 bp in length. Following restriction enzyme digestion with both NsiI and AvaII, patients homozygous for the wild-type allele have restriction fragments 130 bp in length. Those homozygous for the 2C9*3 allele have 140 bp fragments, and those heterozygous for the 2C9*3 allele have 130- and 140-bp fragments. Restriction products were resolved by electrophoresis on a 3% agarose gel. Each amplification reaction (25 µL) contained 50 ng of genomic DNA, 200 µmol/L of each deoxynucleotide triphosphate, 6.25 pmoles of each amplification primer, and 0.2 U of Biotaq DNA polymerase in 2.5 µL of 10 × ammonium buffer (Bioline, London, UK) and 3.0 mmol/L MgCl2. The amplification reactions were carried out in a Perkin Elmer Cetus DNA thermal cycler with an initial denaturation step of 5 minutes at 94°C, followed by 35 cycles of 30 seconds denaturation at 94°C, annealing at 58°C for 30 seconds, and extension at 72°C for 30 seconds with a final extension for 5 minutes at 72°C. After generation of the multiplex PCR products, 0.5µL of AvaII and 1.0µL of NsI I (New England Biolabs, Hitchin, Herts, UK) were added and incubated at 37°C overnight. Restriction products (8 µL) were analyzed by electrophoresis on a 3% agarose gel.Statistics Descriptive statistics were calculated using SPSS software (version 9). The Kruskall-Wallis test was used to compare groups of continuous data for significant differences. A cross-tabulation procedure with calculation of Pearson 2 value was used
to compare groups of categorical data. Odds ratios were calculated by
the logit method using Confidence Interval Analysis software (British
Medical Association, Tavistock Square, London,
UK).15
Study group The 683 patients who had a sample sent to the laboratory for INR measurement during the study period were anonymously genotyped for both the 2C9*2 and 2C9*3 polymorphisms. These patients constituted 48% of the total patient population. The gene frequencies were 84% for 2C9*1, 11% for 2C9*2, and 5% for 2C9*3. Allele frequencies were in Hardy-Weinberg equilibrium.Effect of polymorphisms on maintenance dose of warfarin To study the influence of polymorphisms on the maintenance dose of warfarin all anonymous patient data sets with a target INR of 2.5 were selected from the study group. The 561 patients with a target INR of 2.5 had been genotyped. The only criteria for selection was the target INR. The selection had to be made from the coded data set after genotyping to maintain patient anonymity. The mean doses of warfarin in relation to each combination of alleles are shown in Table 1. The mean maintenance dose of warfarin in patients who were wild type for both alleles was 5.01 mg. The maintenance dose of warfarin was significantly related to genotype (Kruskall-Wallis,2 = 17.985, P = .001).
As a percentage of the mean dose in patients with wild-type alleles
only, the mean warfarin maintenance doses were 86% in 2C9*2
heterozygotes, 79% in 2C9*3 heterozygotes, 82% in compound
heterozygotes for 2C9*2 and 2C9*3, and 61% in
2C9*2 homozygotes.
The frequencies of genotypes in patients with a mean maintenance
warfarin dose of 1.5 mg or less compared to patients with a maintenance
dose more than 1.5 mg are shown in Table
2. The odds ratio for one or more variant
alleles in patients with a maintenance dose of 1.5 mg or less was 3.85 (95% CI 1.24-11.9). This result was due to the influence of
heterozygosity for the 2C9*2 allele (OR 5.42, 95% CI
1.68-17.4). None of 9 patients with 2 variant alleles (6 compound
heterozygotes and 3 2C9*2 homozygotes) had a maintenance
dose of 1.5 mg or less.
Effect of CYP2C9 polymorphisms on risk of INR of 8.0 or greater First analysis was restricted to the 561 patients with a target INR of 2.5. Patients with an INR of 8.0 or greater on at least one occasion were compared to patients with all INRs less than 8.0. The distribution of genotypes is shown in Table 2. There was no difference in the frequency of genotypes between patients with and without INRs of 8.0 or greater (Pearson2 = 4.427,
P = .351). The odds ratios for one variant allele in patients developing an INR of 8.0 or greater was 1.52 (95% CI 0.64-3.58). None of the 9 patients with 2 variant alleles developed an
INR of 8.0 or greater.
A second analysis was performed in patients with a target INR more than
2.5 because these patients are more likely to become over-anticoagulated.16 A total of 117 patients with a
target INR more than 2.5 had been genotyped. Again, there was no
difference in the frequency of genotypes between patients with and
without INRs of 8.0 or greater (Pearson Five of the 683 patients had a target INR of less than 2.5 at the request of the referring clinician. This was not due to a history of bleeding but simply variable practice. Because the target INR is a major determinant of likelihood of over-anticoagulation, these patients would be at lower risk than patients with a target INR of 2.5 or 3.5 and were therefore excluded from the analysis. Effect of CYP2C9 polymorphisms on stability of anticoagulant therapy To study the effect of polymorphisms on warfarin stability, patients with a target INR of 2.5 were selected from the study group. The SD of the mean INR, percentage of high INRs (> 0.5 INR units above target), and person-time in range were determined as parameters of stability. There was no difference between patients grouped according to polymorphism for any parameter. The results are shown in Table 3. A total of 1188 of the original patient population of 1433 had a target INR of 2.5. Overall the mean INR was 2.55, SD 0.85, 19.9% of INRs were more than 0.5 INR units above target and patients were in range 68.2% of the time. Therefore, stability in each of the study groups was comparable to that in the whole patient population.
This study has confirmed an association between CYP2C9 genotype and warfarin sensitivity. However, the possession of a variant allele does not increase the likelihood of severe over-anticoagulation or stability of anticoagulation during long-term therapy. In a previous study we identified a target INR of 3.5 and antibiotic therapy as major risk factors for over-anticoagulation.16 This present study indicates that there is no apparent gene-environment influence from the CYP2C9 locus. In the study of Aithal and colleagues,10 patients with a warfarin dose requirement of 1.5 mg or less immediately after induction of anticoagulation were 6 times more likely to have a variant allele compared to the general population. For the purpose of comparison of studies we also used a warfarin dose requirement of 1.5 mg or less as a parameter of warfarin sensitivity. In our study, patients established on warfarin for more than 2 months were 5 times more likely to have the 2C9*2 allele if their maintenance dose was 1.5 mg or less. There was also a definite dose-response effect due to both variant alleles. The lowest warfarin dose requirement was in 2C9*2 homozygotes whose mean maintenance dose was 40% lower than in wild-type patients. No 2C9*3 homozygotes were identified in our low-dose warfarin group. The expected number based on a 2C9*3 gene frequency of 0.05% is 1.55 with a 95% CI overlapping zero. Therefore, the absence of homozygotes may not be significant. Aithal and coworkers10 also found no 2C9*3 homozygotes. The authors suggested that 2C9*3 homozygotes might have such a low warfarin dose requirement that stabilization is not possible and treatment with warfarin is abandoned. Prospective studies are required to identify such patients and determine if the finding is significant and if this is indeed the explanation. It remains to be determined if early genotyping and dose modification would significantly reduce over-anticoagulation and bleeding in patients during the first few weeks of warfarin therapy. The mechanistic relationship between 2C9 genotype and INR is a function of the catalytic efficiency of the 2C9 enzymatic variants produced by the polymorphic alleles. As a consequence of reduced catalytic activity the dose of warfarin required to produce a standardized intensity of anticoagulation is lower. Thus, when a group of patients with the same target INR, and hence intensity of anticoagulation, was selected, those with 2C9 variants had a lower warfarin maintenance dose requirement. The major complication of long-term oral anticoagulant therapy is over-anticoagulation and bleeding. The risk of bleeding is associated with increasing INR and so identification of genetic and environmental factors that predict the development of a high INR might identify high-risk patients who would be candidates for more frequent monitoring or treatment with an alternative drug. In this study CYP2C9 variant alleles did not increase the likelihood of developing either an INR more than 8.0 or the frequency of an INR more than 0.5 INR units above target. In the primary patient population with a target INR of 2.5, patients were within range 68% of the time. Because warfarin sensitivity is influenced by genotype it seems that once a stable anticoagulant effect is established in patients with variant alleles, though their warfarin dose requirement is lower, their responsiveness is stable and they are not more prone to over-anticoagulation. Our computerized decision support system, which uses an established algorithm, has reduced the incidence of over-anticoagulation in our clinical practice. Only 0.3% of INRs were more than 8.0. However, over an average treatment period of 2.5 years 5% of the patients had at least one INR more than 8.0. The CYP2C9 locus is not associated with the development of a high INR during long-term therapy. A missense mutation at ALA-10 in the factor IX propeptide increases the risk of bleeding without affecting the INR.17 However, this mutation is rare and prospective genotyping of patients starting oral anticoagulant therapy cannot be justified.18,19 As the pharmogenomics of warfarin-drug interactions is unraveled, genetic analysis may yet prove to have a role in the assessment of risk and management decisions relating to type of anticoagulant, frequency of monitoring, and optimum duration of therapy.
We are grateful to Caroline Baglin, Haemostasis Nurse Specialist, for coordinating the Anticoagulant Service and Roger Luddington, Clinical Scientist, for the INR measurements.
Submitted February 23, 2000; accepted May 8, 2000.
Supported by Chiroscience R&D Ltd.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Trevor Baglin, Department of Haematology, Addenbrooke's NHS Trust, Cambridge, CB2 2QQ, United Kingdom; e-mail: tpb20{at}cam.ac.uk.
1.
van der Meer F, Rosendaal F, Vandenbroucke J, Briet E.
Bleeding complications in oral anticoagulant therapy.
Arch Intern Med.
1993;153:1557
2.
Cannegieter S, Rosendaal F, Wintzen A, Van Der Meer F, Vandenbroucke J, Briet E.
Optimal oral anticoagulant therapy in patients with mechanical heart valves.
N Engl J Med.
1995;333:11 3. Palareti G, Leali N, Coccheri S, et al. on behalf of the Italian Study on Complications of Oral Anticoagulant Therapy. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996;348:423[Medline] [Order article via Infotrieve].
4.
Eckman M, Levine H, Pauker S.
Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy.
N Engl J Med.
1993;329:696 5. British Committee for Standards in Haematology. Guidelines on oral anticoagulation: third edition. Br J Haematol 1998;101:374[Medline] [Order article via Infotrieve]. 6. Strubbins M, Harries L, Smith G, Tarbit M, Wolf C. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics. 1996;6:429[Medline] [Order article via Infotrieve]. 7. Rettie A, Wienkers L, Gonzalez F, Trager W, Korzekwa K. Impaired S-warfarin metabolism catalysed by R144C allelic variant of CYP2C9. Pharmacogenetics. 1994;4:39[Medline] [Order article via Infotrieve]. 8. Haining R, Hunter A, Veronese M, Trager W, Rettie A. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression purification, structural characterisation, substrate streoselectivity and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys. 1996;333:447[Medline] [Order article via Infotrieve]. 9. Crespi C, Miller V. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics. 1997;7:203[Medline] [Order article via Infotrieve]. 10. Aithal G, Day C, Kesteven P, Daly A. Association of polymorphisms in the cytochrtome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353:717[Medline] [Order article via Infotrieve]. 11. Baglin T, Luddington R. Reliability of delayed INR determination: implications for decentralised anticoagulant care with off-site blood sampling. Br J Haematol. 1997;96:431[Medline] [Order article via Infotrieve]. 12. Baglin T. Decentralised anticoagulant care. J Clin Pathol 1998;51:89[Medline] [Order article via Infotrieve]. 13. Wilson R, James A. Computer assisted management of warfarin treatment. BMJ. 1984;289:422. 14. Rosendaal F, Cannegieter S, van der Meer F, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236[Medline] [Order article via Infotrieve].
15.
Gardner M, Altman D.
Statistics with Confidence 16. Panneerselvam S, Baglin C, Lefort W, Baglin T. Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin. Br J Haematol. 1998;103:422[Medline] [Order article via Infotrieve]. 17. Chu K, Wu S, Stanley T, Stafford D, High K. A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest 1996;98:1619[Medline] [Order article via Infotrieve]. 18. Oldenburg J, Quenzel E, Harbretcht U, et al. Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life bit a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 1997;98:240[Medline] [Order article via Infotrieve]. 19. Peters J, Luddington R, Brown K, Baglin C, Baglin T. Should patients starting anticoagulant therapy be screened for missense mutations at ALA-10 in the factor IX propeptide? Br J Haematol 1997;99:467[Medline] [Order article via Infotrieve].
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  F. Marin, R. Gonzalez-Conejero, P. Capranzano, T. A. Bass, V. Roldan, and D. J. Angiolillo Pharmacogenetics in cardiovascular antithrombotic therapy. J. Am. Coll. Cardiol., September 15, 2009; 54(12): 1041 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Rosove and W. W. Grody Should We Be Applying Warfarin Pharmacogenetics to Clinical Practice? No, Not Now Ann Intern Med, August 18, 2009; 151(4): 270 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The Genes for Cerebral Hemorrhage on Anticoagulati Exploiting Common Genetic Variation to Make Anticoagulation Safer Stroke, March 1, 2009; 40(3_suppl_1): S64 - S66. [Full Text] [PDF]
|
|
|
|
|
|
M. H. Eckman, J. Rosand, S. M. Greenberg, and B. F. Gage Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation Ann Intern Med, January 20, 2009; 150(2): 73 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M Hynicka, W. D Cahoon Jr, and B. L Bukaveckas Genetic Testing for Warfarin Therapy Initiation Ann. Pharmacother., September 1, 2008; 42(9): 1298 - 1303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. G Watson and M. Greaves Review: New anticoagulants: a story of promise and disappointment The British Journal of Diabetes & Vascular Disease, March 1, 2007; 7(2): 51 - 58. [Abstract] [PDF]
|
|
|
|
 |
|
 S. J. Gardiner and E. J. Begg Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. van Walraven, A. Jennings, N. Oake, D. Fergusson, and A. J. Forster Effect of Study Setting on Anticoagulation Control: A Systematic Review and Metaregression Chest, May 1, 2006; 129(5): 1155 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Wiwanitkit Pharmacogenomic Effect of Cytochrome P450 2C9 Polymorphisms in Different Populations Clinical and Applied Thrombosis/Hemostasis, April 1, 2006; 12(2): 219 - 222. [Abstract] [PDF]
|
|
|
|
 |
|
 B. F. Gage Pharmacogenetics-Based Coumarin Therapy Hematology, January 1, 2006; 2006(1): 467 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Sconce, T. I. Khan, H. A. Wynne, P. Avery, L. Monkhouse, B. P. King, P. Wood, P. Kesteven, A. K. Daly, and F. Kamali The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen Blood, October 1, 2005; 106(7): 2329 - 2333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Hillman, R. A. Wilke, S. H. Yale, H. J. Vidaillet, M. D. Caldwell, I. Glurich, R. L. Berg, J. Schmelzer, and J. K. Burmester A Prospective, Randomized Pilot Trial of Model-Based Warfarin Dose Initiation using CYP2C9 Genotype and Clinical Data Clin. Med. Res., August 1, 2005; 3(3): 137 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bodin, C. Verstuyft, D.-A. Tregouet, A. Robert, L. Dubert, C. Funck-Brentano, P. Jaillon, P. Beaune, P. Laurent-Puig, L. Becquemont, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity Blood, July 1, 2005; 106(1): 135 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A M Hall and M R Wilkins Warfarin: a case history in pharmacogenetics Heart, May 1, 2005; 91(5): 563 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D'Andrea, R. L. D'Ambrosio, P. Di Perna, M. Chetta, R. Santacroce, V. Brancaccio, E. Grandone, and M. Margaglione A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin Blood, January 15, 2005; 105(2): 645 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Funk, G. Endler, R. Freitag, J. Wojta, K. Huber, C. Mannhalter, and R. Sunder-Plassmann CYP2C9*2 and CYP2C9*3 Alleles Confer a Lower Risk for Myocardial Infarction Clin. Chem., December 1, 2004; 50(12): 2395 - 2398. [Full Text] [PDF]
|
|
|
|
 |
|
 J P Hanley Warfarin reversal J. Clin. Pathol., November 1, 2004; 57(11): 1132 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kim, J. A. Johnson, and H. Derendorf Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms J. Clin. Pharmacol., October 1, 2004; 44(10): 1083 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Marks, D. V. Thompson, T. A. Goossens, and O. V. Trubetskoy High-Throughput Screening Assays for the Assessment of CYP2C9*1, CYP2C9*2, and CYP2C9*3 Metabolism Using Fluorogenic Vivid(R) Substrates J Biomol Screen, August 1, 2004; 9(5): 439 - 449. [Abstract] [PDF]
|
|
|
|
|
|
J. D. Ma, A. N. Nafziger, and J. S. Bertino Jr. Genetic Polymorphisms of Cytochrome P450 Enzymes and the Effect on Interindividual, Pharmacokinetic Variability in Extensive Metabolizers J. Clin. Pharmacol., May 1, 2004; 44(5): 447 - 456. [Abstract] [Full Text]
|
|
|
|
|
|
E. Shikata, I. Ieiri, S. Ishiguro, H. Aono, K. Inoue, T. Koide, S. Ohgi, and K. Otsubo Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and {gamma}-glutamyl carboxylase) gene variants with warfarin sensitivity Blood, April 1, 2004; 103(7): 2630 - 2635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Malhi, B Atac, A K Daly, and S Gupta Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication Postgrad. Med. J., February 1, 2004; 80(940): 107 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Orphanides and I. Kimber Toxicogenetics: Applications and Opportunities Toxicol. Sci., September 1, 2003; 75(1): 1 - 6. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W E Evans Pharmacogenomics: marshalling the human genome to individualise drug therapy Gut, May 1, 2003; 52(90002): ii10 - 18. [Abstract] [Full Text]
|
|
|
|
|
|
P. R. Gentry, C. E. Hack, L. Haber, A. Maier, and H. J. Clewell III An Approach for the Quantitative Consideration of Genetic Polymorphism Data in Chemical Risk Assessment: Examples with Warfarin and Parathion Toxicol. Sci., November 1, 2002; 70(1): 120 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zarza, J. Hermida, R. Montes, I. Alberca, M. L. Lopez, and E. Rocha Leu208Val and Ile181Leu variants of cytochrome P450 CYP2C9 are not related to the acenocoumarol dose requirement in a Spanish population Blood, June 28, 2002; 100(2): 734 - 735. [Full Text] [PDF]
|
|
|
|
|
|
J. Hermida, J. Zarza, I. Alberca, R. Montes, M. L. Lopez, E. Molina, and E. Rocha Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol Blood, May 13, 2002; 99(11): 4237 - 4239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Higashi, D. L. Veenstra, L. M. Kondo, A. K. Wittkowsky, S. L. Srinouanprachanh, F. M. Farin, and A. E. Rettie Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin Therapy JAMA, April 3, 2002; 287(13): 1690 - 1698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Phillips, D. L. Veenstra, E. Oren, J. K. Lee, and W. Sadee Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review JAMA, November 14, 2001; 286(18): 2270 - 2279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Y. H. Leung, H. C. H. Chow, Y. L. Kwong, A. K. W. Lie, A. T. K. Fung, W. H. Chow, A. S. B. Yip, and R. Liang Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients Blood, October 15, 2001; 98(8): 2584 - 2587. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
80°C until
analysis. Genotyping was performed on completion of sample collection.
After analysis the CYP2C9 genotypes were matched to the
coded anonymous database. No additional blood or tissue was taken from
any patient for the purpose of this study.
Confidence Intervals and Statistical Guidelines. London: British Medical Journal; 1989.